Implementing microbicides in low-income countries

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 26, Issue 4, 2012, Pages 495-501

  Gengiah, Tanuja N ^a   Abdool Karim, Quarraisha ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

HIV prevention; implementation; low income countries; microbicides

Indexed keywords

MICROBICIDE; TENOFOVIR;

CLINICAL EFFECTIVENESS; CONDOM; DECISION MAKING; DEVELOPING COUNTRY; DISEASE COURSE; DRUG EFFICACY; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH SERVICE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LOWEST INCOME GROUP; MICROBIAL DIVERSITY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL TRANSMISSION; UNSAFE SEX;

EID: 84862847422     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2012.02.004     Document Type: Article

References (27)

1. UNAIDS. UNAIDS world AIDS day report 2011. Geneva: Joint United Nations Programme on HIV/AIDS, 2011, http://www. unaids.org/en/media/unaids/ contentassets/documents/unaidspublication/2011/JC2216-WorldAIDSday-report-2011- en.pdf [last accessed 24.02.12].
2. Centres for Disease Control. HIV surveillance report: diagnoses of HIV infection and AIDS in the United States and dependent areas 2009, http://www.cdc.gov/hiv/surveillance/resources/reports/2009report/index.htm [last accessed 24.02.12].
3. Leclerc-Madlala S. Age-disparate and intergenerational sex in southern Africa: the dynamics of hypervulnerability. AIDS 2008; 22(Suppl. 4): S17-S25.
4. Luke N. Age and economic asymmetries in the sexual relationships of adolescent girls in sub-Saharan Africa. Stud Fam Plann 2003; 34: 67-86. (Pubitemid 36947043)
5. Task force report on women and girls in southern Africa. Geneva: UNAIDS, 2004.
6. Lagakos SW & Gable AR. Challenges to HIV prevention: seeking effective measures in the absence of a vaccine [comment]. N Engl J Med 2008; 358: 1543-1545. (Pubitemid 351519815)
7. *Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-1174.
8. Vermund SH & Van Damme L. HIV prevention in women [letter]: next steps. Science 2011; 331: 284.
9. ClinicalTrials.gov. FACTS 001: safety and effectiveness of tenofovir gel in the prevention of human immunodeficiency virus (HIV- 1) infection in young women and the effects of tenofovir gel on the incidence of herpes simplex virus (HSV-2) infection 24 October 2011, http://clinicaltrials.gov/ct2/show/ NCT01386294?term=facts+001&rank=1 [last accessed 24.02.12].
10. *Williams BG, Abdool Karim SS, Karim QA et al. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr 2011; 58: 207-210.
11. Verma NA, Lee AC, Herold BC et al. Topical prophylaxis for HIV prevention in women: becoming a reality. Curr HIV/AIDS Rep 2011; 8: 104-113.
12. *Karim SS & Karim QA. Antiretroviral prophylaxis: a defining moment in HIV control. Lancet 2011; 378: e23-e25.
13. Underhill K, Operario D, Skeer M et al. Packaging PrEP to prevent HIV: an Integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquir Immune Defic Syndr 2010; 55: 8-13.
14. Underhill K, Operario D, Mimiaga MJ et al. Implementation science of pre-exposure prophylaxis: preparing for public use [review]. Curr HIV/AIDS Rep 2010; 7: 210-219.
15. *Shelton JD. HIV/AIDS. ARVs as HIV prevention: a tough road to wide impact. Science 2011; 334: 1645-1646.
16. *Shelton JD. Twenty criteria to make the best of scarce health resources in developing countries. BMJ 2011; 343: d7023.
17. Kelly CG & Shattock RJ. Specific microbicides in the prevention of HIV infection. J Intern Med 2011; 270: 509-519.
18. Padian NS, McCoy SI, Karim SS et al. HIV prevention transformed: the new prevention research agenda. Lancet 2011; 378: 269-278.
19. Barker PM, Mphatswe W & Rollins N. Antiretroviral drugs in the cupboard are not enough: the impact of health systems' performance on mother-to-child transmission of HIV. J Acquir Immune Defic Syndr 2011; 56: e45-e48.
20. Frenk J, Chen L, Bhutta ZA et al. Health professionals for a new century: transforming education to strengthen health systems in an interdependent world. Lancet 2010; 376: 1923-1958.
21. *Frenk J. The global health system: strengthening national health systems as the next step for global progress. PLoS Med 2010; 7: e1000089.
22. Schackman BR. Implementation science for the prevention and treatment of HIV/AIDS. J Acquir Immune Defic Syndr 2010; 55(Suppl. 1): S27-S31.
23. *Berwick DM. Continuous improvement as an ideal in health care. N Engl J Med 1989; 320: 53-56. (Pubitemid 19033064)
24. Richardson WC, Berwick DM & Bisgard JC. The Institute of Medicine report on medical errors. N Engl J Med [letter] 2000; 343: 663-664.
25. Berwick DM. Disseminating innovations in health care. JAMA 2003; 289: 1969-1975. (Pubitemid 37430229)
26. *Barker PM, McCannon CJ, Mehta N et al. Strategies for the scale-up of antiretroviral therapy in South Africa through health system optimization. J Infect Dis 2007; 196(Suppl. 3): S457-S463. (Pubitemid 351419183)
27. *Doherty T, Chopra M, Nsibande D et al. Improving the coverage of the PMTCT programme through a participatory quality improvement intervention in South Africa. BMC Public Health 2009; 9: 406.